
IPO
AFMD.NASDAQ
Minulé
Affimed
Biotechnology
Stránky společnostiTicker
AFMD.NASDAQ
Trh
us
Rok založení
2000
Datum IPO
1/13/2021
O společnosti
Total Funding
$521.9M
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Number of employees
101 - 250
Headquarters
Heidelberg, Baden-Wurttemberg, Germany